Skip to main content

Time in Range

What's new

A clinical trial by Lilly is seeing if your Time in Range could improve from taking Lyumjev, a ultra-rapid mealtime insulin, along with long acting insulin glargine. Continue Reading »

If you are currently taking three or more insulin injections per day, you may be eligible to participate in a clinical trial that provides you with the Guardian Connect continuous glucose monitor (CGM) system, InPen smart insulin pen, and smart insulin pen caps. Continue Reading »

Results from recent clinical trials have shown that GLP-1 receptor agonist medications are effective at lowering A1C and body weight.  Continue Reading »

The recent release of clinical trial results shows that Omnipod 5, an automated insulin delivery (AID) system, can significantly increase Time in Range and reduce stress around managing diabetes. Continue Reading »

Diabeloop’s AID system can improve Time in Range and quality of life for people with type 1 diabetes. Read below to learn more.  Continue Reading »

diaTribe is excited to bring you additional expanded coverage from the EASD 2021 virtual conference this past week! Find out more from leading clinicians and researchers around the world on insights into the latest data on automated insulin delivery, diet and nutrition, SGLT-2s, GLP-1s, and chronic kidney disease. Continue Reading »

diaTribe partnered with Abbott and Novo Nordisk to bring you the Time in Range Hub – a new online resource to help you and your healthcare providers learn about Time in Range. Read more about this exciting new website below.  Continue Reading »

Studies show that if you have diabetes, increasing your Time in Range (TIR) can lower your risk of developing kidney disease. Learn how kidney disease is diagnosed, why A1C has limitations for people with CKD, and the link between your TIR and your risk for kidney disease. Continue Reading »

Pages